Paloma Partners Management CO Sage Therapeutics, Inc. Transaction History

Paloma Partners Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $1.78 Million - $2.71 Million	-30,467 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $650,059 - $987,022	-15,805 Reduced 34.16%	30,467 $1.86 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $1.2 Million - $2 Million	46,272 New	46,272 $1.92 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $137,451 - $353,494	-2,284 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $320,422 - $433,868	2,284 New	2,284 $320,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $14.5 Million - $17.7 Million	-104,899 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $14.7 Million - $18.4 Million	104,899 New	104,899 $16.4 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $336,251 - $425,049	-2,210 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $126,297 - $348,067	-2,080 Reduced 48.48%	2,210 $363,000
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $263,406 - $379,750	4,290	4,290 $268,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $303M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.